Clinical trials: Atopic Dermatosis
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
Part A To measure and compare the amount of study drug in the blood after a single 200 mg dose of study drug given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions To measure and…
- Trial name
- NCT04065633
- Testing
- P3-Fast, Comm-Fast, Vari-Fast
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Dermatitis Atopic
A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
Primary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment.
- Trial name
- AD-impaCT (NCT05214326)
- Where
- 3 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 187 people
- Sponsor
- Sanofi
Atopic Dermatitis, Atopic Dermatitis Eczema
Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
- Trial name
- NCT07734415
- Testing
- IMG-007
- Where
- 23 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Inmagene LLC
Atopic Dermatitis, Asthma
Prospective Longitudinal Observational Research in Atopic Dermatitis
Atopic dermatitis (AD) is a frequent chronic relapsing inflammatory skin disorder, characterized by intensely itchy eczema. AD usually starts within the first 2 years of life.
- Conditions
- Atopic Dermatitis, Asthma, Atopic Dermatitis and Related Conditions
- Trial name
- ProRaD (NCT04240522)
- Where
- Switzerland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Atopic Dermatitis, Acne
Electrochemistry Measurement of Skin Hydration Parameters
To date measuring the effect of dermocosmetic products on the main identified factors of aging and alteration of the skin barrier is based on invasive and expensive experiments.
- Conditions
- Atopic Dermatitis, Acne, Skin Electrochemistry
- Trial name
- SKINBIOSENSE (NCT05071456)
- Testing
- Collects of skin's hydration
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dermatitis, Atopic
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
A Phase 1, Open Label, Parallel-Cohort, Randomized, Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between PF-04965842 and Fkuvoxamine (cohort 1) or Fluconazole (Cohort 2) in healthy subjects.
- Trial name
- NCT03634345
- Testing
- Period 1 - Day 1: PF-04965842 administered, Period 2: Cohort 1: Fluvoxamine & PF-04965842, Period 2: Cohort 2: Fluconazole & PF-04965842
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis
Natural History of Severe Allergic Inflammation and Reactions
Background: Allergic inflammation is central to allergy-related diseases and disorders, such as asthma, food allergies, and atopic dermatitis.
- Conditions
- PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis, OSMR Deficiency, Primary Localized Cutaneous Amyloidosis
- Trial name
- NCT01164241
- Where
- United States
- Volunteers
- 945 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side…
- Trial name
- NCT04922021
- Testing
- LEO 138559
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in Pediatric Subjects Affected by Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, multifactorial inflammatory skin disease characterized by eczematous skin and pruritus and it's due to an alteration of the skin barrier and of the intestinal and skin microbiome (SM), which…
- Trial name
- BuPAD (NCT07016087)
- Testing
- Cosmetic formulation experimental, Cosmetic formulation usual
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University
Atopic Dermatitis
A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis
A randomised, adaptive design, double-blind, placebo-controlled, first-in-human, two-part study to investigate the safety, tolerability, PK and preliminary efficacy of multiple topical doses of BEN2293 in patients with mild to…
- Trial name
- NCT04737304
- Where
- United Kingdom
- Volunteers
- 123 people
- Sponsor
- BenevolentAI Bio
Atopic Dermatitis
A Study Evaluating TRIV-573 in Atopic Dermatitis
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.
- Trial name
- NCT07782333
- Testing
- TRIV-573
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Triveni Bio
Eczema/Atopic Dermatitis, Cancer
Patient Forward Access to Clinical and Technological Research: Genetic Influences on Cancer and Atopic Dermatitis
This Patient Forward study intends to conduct research to investigate potential genetic factors causing cancer and eczema/atopic dermatitis.
- Trial name
- PFACTR02 (NCT04362852)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Atopic Dermatitis
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
The objective of the proposed study is to evaluate the tolerability and effectiveness of a 1% topical ointment of tofacitinib for the treatment of mild to moderate atopic dermatitis in adults.
- Trial name
- NCT05487963
- Testing
- Tofacitinib Citrate
- Where
- Georgia
- Volunteers
- 40 people
- Sponsor
- CAGE Bio Inc.
Atopic Dermatitis
Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment.
- Trial name
- AD-Sys (NCT05098821)
- Testing
- not applicable, observational study
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Charite University, Berlin, Germany
Atopic Dermatitis
Emollients in the Management of Atopic Dermatitis
The purpose of this study is to confirm that emollients play a major role in the maintenance therapy after clearing of inflammatory lesions and can reduce occurrence of flares in children with atopic dermatitis.
- Trial name
- NCT01779258
- Testing
- glycerol, paraffin (liquid and white soft), Atopiclair®, Locatop@
- Where
- 15 sites in Estonia, France and 3 more
- Volunteers
- 347 people
- Sponsor
- Pierre Fabre Medicament
Dermatitis, Dermatitis, Atopic
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- NCT03627767
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 235 sites in United States, Argentina and 19 more
- Volunteers
- 1,235 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis
The study's objective is to confirm that RHT-3201 reduces the signs and symptoms of moderate atopic dermatitis determined by SCORAD, in patients aged 1 to 12 years, as compared to placebo.
- Trial name
- NCT03907228
- Testing
- RHT-3201
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Atopic Dermatitis (AD), Atopic Eczema
Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema
This randomized controlled trial (RCT) aims to evaluate the efficacy and safety of Crisaborole 2% cream compared with placebo in patients with mild to moderate atopic dermatitis (AD), also known as atopic eczema.
- Trial name
- CRISA-AD (NCT07438509)
- Testing
- Crisaborole 2% Cream
- Volunteers
- 270 people
- Sponsor
- Jinnah Postgraduate Medical Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.